

Press Release, 27 April 2016

Prospectus relating to IBT's rights issue published

The prospectus relating to Infant Bacterial Therapeutics AB's (publ) ("IBT") rights issue has now been published and is available on IBT's and Carnegie Investment Bank's webpages, www.ibtherapeutics.com and www.carnegie.se, respectively. The prospectus can also be ordered from IBT by telephone +46 8 410 145 55 or from Carnegie Investment Bank by telephone +46 8 5886 94 87.

For additional information please contact

Staffan Strömberg, CEO, phone: +46 8 410 145 55

Peter Rothschild, chairman, phone: +46 8 410 145 55

Infant Bacterial Therapeutics AB (publ)

Bryggargatan 10

111 21 Stockholm

Phone: +46 8 410 145 55

info@ibtherapeutics.com

IBT discloses this information in accordance with the Swedish Securities Market Act. The information was provided for publication at 8:30 PM on 27 April 2016.

Infant Bacterial Therapeutics AB ("IBT") is a pharmaceutical company based in Stockholm that develops drugs that meet the needs of the premature infants. IBT's current focus is on clinical development of IBP-9414, a drug candidate containing *Lactobacillus reuteri*, in the prevention of necrotizing enterocolitis ("NEC"), a fatal disease that affects premature infants. IBT is listed on Nasdaq First North with Erik Penser Bankaktiefbolag as Certified adviser.

www.ibtherapeutics.com

IMPORTANT INFORMATION

This press release is not a prospectus or an offer to subscribe for shares in IBT and an investor shall not subscribe for or purchase any securities, except on the basis of information provided in the prospectus.

This press release may not be made public, released or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, Singapore, South Africa or New Zealand or in any other jurisdiction in which the distribution of this press release would be unlawful. Further, this press release does not constitute an offer to sell new shares, paid subscribed for shares ("BTA") or subscription rights to any person in any jurisdiction in which it is unlawful to make such offer to such person or where such action would require additional prospectuses, registration or other measures other than those pursuant to Swedish law. The prospectus, application forms and other documents associated with the rights issue may not be distributed in or to any country where such distribution or the rights issue would require such measures set forth in the preceding sentence or be in violation of the regulations of such country.

The new shares, BTAs and subscription rights have not been recommended by a United States federal or state securities commission or regulatory authority. No new shares, BTAs, subscription rights or other securities issued by IBT have been or will be registered under the U.S. Securities Act of 1933, as amended, or under the securities legislation in any state of the United States or any province in Canada. Accordingly, no new shares, BTAs, subscription rights or other securities issued by IBT may be transferred or offered for sale in the United States or Canada, other than in such exceptional cases that do not require registration. The securities issued in the rights issue will not be offered to the public in the United States.

IBT has not authorized any offer of securities to the public in any country in the European Economic Area ("EEA") other than Sweden. In other member states in the EEA which have implemented the Directive 2003/71/EC (the "Prospectus Directive") (each, a "Relevant Member State"), no action has been undertaken and will not be undertaken to make an offer of securities to the public requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States to (a) any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) any person falling within Article 3(2) of the Prospectus Directive.

The rights issue is only directed at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order (all such persons together being referred to as "relevant persons"). The securities issued in the rights issue will only be available to and will only be engaged with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Infant Bacterial Therapeutics AB ("IBT") is a pharmaceutical company based in Stockholm that develops drugs that meet the needs of the premature infants. IBT's current focus is on clinical development of IBP-9414, a drug candidate containing *Lactobacillus reuteri*, in the prevention of necrotizing enterocolitis ("NEC"), a fatal disease that affects premature infants. IBT is listed on Nasdaq First North with Erik Penser Bankaktiebolag as Certified adviser.

www.ibtherapeutics.com